AzTrials
AzTrials

Recurrent or Metastatic Colorectal CancerPhase 1/2NCT05990543

Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer

A Phase 1/2 study testing Nelmastobart and Capecitabine in people with Recurrent or Metastatic Colorectal Cancer, run by Korea University Anam Hospital at 1 site in South Korea.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This is an open-label clinical trial aimed at evaluating the safety and efficacy of the combination treatment of nelmastobart with capecitabine in patients diagnosed with metastatic or recurrent colorectal cancer. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
Nelmastobart and Capecitabine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
59 participants
Where
1 siteSouth Korea
Study dates
29 Jan 2024to 31 Dec 2026
Phase
Phase 1/2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Male or female subject ≥18 years of age at the time of signing the informed consent form (ICF).
  • Subjects with histologically or cytologically confirmed colorectal adenocarcinoma who have failed or are ineligible for oxaliplatin and irinotecan-based chemotherapy.
  • Subjects with advanced/metastatic solid tumors, with evaluable lesion as determined by Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1.
  • Measurable lesion is optional.
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤2.
  • Adequate organ and bone marrow function characterized by the following at screening:
Show all 23Show fewer
  • Absolute neutrophil count(ANC) ≥1.0 × 109/L;b.
  • Platelets ≥75 × 109/L;c.
  • Hemoglobin ≥9.0 g/dL (with or without blood transfusions).
  • Adequate renal function defined by Serum creatinine ≤ ULN x 1.5 or an estimated creatinine clearance ≥30 mL/min according to the Cockcroft Gault formula or by 24-hour urine collection for creatinine clearance, or according to local institutional standard method.
  • Serum total bilirubin ≤2.0 x upper limit normal (ULN), if a subject with biliary obstruction is considered suitable if they meet the criteria after appropriate bile drainage.
  • ALT and AST ≤ 3 × ULN, or ≤5 × ULN in the presence of liver metastases.
  • Adequate cardiac function: QTc ≤480 msec; if QTc exceeds 480 msec, subjects can be enrolled if the average QTc value is less than 480 msec by measuring 3 times consecutively in total.
  • The subject is able to swallow and retain oral medication
  • Serum β hCG test negative within 14 days before the first administration of the study treatment (women of childbearing potential only)
  • Requirement for contraception must be observed by the subject.
  • Eligible women (all women of reproductive potential who are either undergoing clinical trial treatment or within 4 weeks after discontinuing clinical trial treatment, and who are not using appropriate contraception) must use the following contraceptive methods to be eligible for enrollment.
  • Subjects must abstain from all forms of sexual intercourse and are encouraged to practice consistent abstinence in their daily lives. Periodic abstinence methods (e.g., calendar-based methods, cervical mucus observation, basal body temperature methods, etc.) and withdrawal are not considered acceptable contraceptive methods.
  • Accepted infertility surgical procedures: Bilateral oophorectomy with or without hysterectomy; Tubal ligation at least 6 weeks before enrollment in this clinical trial. Bilateral oophorectomy is only allowed if the subject's potential for pregnancy is confirmed through hormone level assessment.
  • In the case of female participants in the clinical trial, their male partners who have undergone vasectomy (screening performed at least 6 months prior) should be their exclusive partners during the participation in this clinical trial
  • During the clinical trial, male participants should use condoms during sexual intercourse while they are receiving the investigational drug and for up to 1 month after discontinuing the treatment (after the last dose).
  • Life expectancy of at least 12 weeks. Capable and willing to give signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.
  • Subject has signed the Informed Consent Form (ICF) prior to any screening procedures being performed

Who cannot join

  • Patient has a known or suspicious hypersensitivity to fluoropyrimidines.
  • Any cytotoxic chemotherapy from a previous treatment regimen within 14 days. If the subject received an investigational drug from another clinical trial, the subject can be enrolled after 2 weeks of last administration and more than 5 x half-life of the investigational drug. If monoclonal antibody therapy was given, the subject can be enrolled after four weeks after the last dose.
  • Uncontrolled severe infection
  • Subjects with conditions requiring high doses of steroids (>10 mg/day of prednisone or equivalent) or other immunosuppressive medications are excluded, all of the following will not be excluded:
  • Brief (<7 days) use of systemic corticosteroids is allowed when use is considered standard of care.
  • Subjects requiring intermittent use of bronchodilators, inhaled steroids, or local steroid injections will not be excluded.
Show all 24Show fewer
  • Replacement therapy (e.g., thyroxine, insulin, physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
  • Subjects who are pregnant or breastfeeding women.
  • History of autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Subjects with vitiligo, psoriasis not requiring systemic treatment, type 1 diabetes mellitus, hypothyroidism stable with hormone replacement, Sjögren's syndrome, or resolved childhood asthma/atopy will not be excluded.
  • Active central nervous system (CNS) lesions (i.e., those with radiologically unstable or symptomatic brain lesions). For those who receive radiation or surgical treatment, the subject can be enrolled if the subject is maintained without steroid therapy and the evidence of CNS disease progression for more than 4 weeks. However, patients with leptomeningeal metastases are excluded.
  • Subjects with a documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association (NYHA) Class IV within 6 months prior to screening.
  • Subjects with a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computerized tomography (CT) scan.
  • Subjects who have received a prior allogeneic stem cell or solid organ transplant.
  • Subjects who have received a live attenuated vaccine within 30 days prior to screening. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
  • History of other primary cancer. Exceptions are as follows:
  • Adequately treated non-melanoma skin cancer (basal cell or squamous cell carcinoma), curatively treated in situ cancer of the cervix or stage I bladder cancer, completely resected thyroid cancer without distant metastasis in which all treatment has been completed (Appropriate wound healing is required prior to clinical trial enrollment)
  • Subject has not recovered to ≤ grade 1 (except alopecia) from related adverse effects of any prior anticancer therapy.
  • Radiotherapy with a wide field (more than 30% of the bone marrow) of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study treatment.
  • Subject who has undergone major surgery ≤ 4 weeks prior to starting study treatment or who has not recovered from adverse effects of such procedure.
  • Subjects with impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of capecitabine.
  • Subjects who have known active hepatitis B (defined as positive hepatitis B surface antigen [HBsAg] with detected hepatitis B virus [HBV] DNA) or known active hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.
  • Subjects with genetic conditions such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
  • As judged by the Investigator, all other symptoms and associated disease for which the investigator determined that participation in this study is contraindicated (e.g. Infection/inflammation; severe liver dysfunction; bilateral diffuse interstitial lung disease; uncontrolled renal disease; unstable heart and lung disease; hemorrhagic disease; intestinal obstruction; unable to swallow oral pills; social and psychological problems, etc.)
  • Medical, psychiatric, cognitive, or other conditions that may interfere with the ability of the subject to understand the subject information, provide the informed consent, follow the protocol process, or complete the clinical trial

Trial locations and contacts

1 site in 1 country.

South Korea1 site

  • Korea University Medical Center 73, Goryeodae-ro, Seongbuk-gu

    Seoul, Seoul, 02841

Other trials in South Korea

About this study

Official title: Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer With Resistance or Intolerance to Oxaliplatin and Irinotecan-based Chemotherapy - A Single Arm, Phase 1b/2, Multicenter Study

This is an open-label clinical trial aimed at evaluating the safety and efficacy of the combination treatment of nelmastobart with capecitabine in patients diagnosed with metastatic or recurrent colorectal cancer.

Read the detailed description

Colorectal cancer is the third most commonly diagnosed cancer in men and the second most common cancer in women worldwide, with an estimated 1.9 million new cases and 935,000 deaths in 2020, according to the World Health Organization. Patients with metastatic colorectal cancer typically undergo first-line treatment consisting of fluorouracil-based chemotherapy (oxaliplatin and irinotecan) with or without vascular endothelial growth factor (VEGF)-based therapy (primarily bevacizumab), and epidermal growth factor receptor (EGFR)-targeted therapies (in patients with RAS wild-type tumors). Second-line treatment options may include alternative chemotherapy regimens. Third-line treatment options are often limited for patients with metastatic colorectal cancer, as they tend to exhibit poor objective response rates and short progression-free survival. However, despite their good performance status, patients often encounter limited options for third-line treatment, resulting in a daunting and frustrating situation.

This study will enroll patients aged ≥18 years who are resistant or intolerant to oxaliplatin and irinotecan-based chemotherapy. The study will evaluate the safety of the Nelmastobart and capecitabine combination therapy in Phase 1b. After identifying the Recommended Phase 2 Dose (RP2D), the study will assess the efficacy of the Nelmastobart and capecitabine combination therapy in Phase 2.

Being tested
Nelmastobart and Capecitabine
Keywords
colorectal cancer, immunotherapy
Medical subject headings
Recurrence, Colorectal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Nelmastobart and CapecitabineDrug

    Nelmastobart intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered on Day 1 of each cycle.

    Capecitabine is administered orally for two weeks followed by a one-week rest period

Study groups in NCT05990543
Study groupRoleWhat they receive
Group 1ExperimentalNelmastobart + Capecitabine
Receives: Drug: Nelmastobart and Capecitabine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maximum Tolerated Dose

    The MTD was defined as the highest dose at which no dose limiting toxicity (DLT) was experienced by the first 3 patients in that cohort, or the dose at which a DLT was experienced by no more than 1 of 6 patients evaluable for toxicity.

    Measured: Up to approximately 2 years

  2. Progression free survival

    PFS events is defined as the interval from the first dose of investigational treatment to the earlier of the first documentation of objective progressive disease (PD) or death from any cause,whichever comes first.

    Measured: Up to approximately 2 years

Secondary outcomes (2)

  1. Overall response rate

    ORR is defined as the proportion of participants who achieve a CR or PR as assessed by RECIST v1.1.

    Measured: Up to approximately 2 years

  2. Overall survival

    Progression free survival (PFS) will be calculated from the first dose of investigational treatment until date of progression or death without progression, using the Kaplan-Meier method accompanied by determination of the median and its 95% confidence interval.

    Measured: Up to approximately 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Aug 2023
  2. Study start29 Jan 2024
  3. Primary completion1 Dec 2025 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
59 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05990543
Sponsor's protocol ID
NelCap001
Status last verified
Feb 2025
First submitted
28 Jul 2023
Last updated
8 Sep 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Nelmastobart and Capecitabine in people with Recurrent or Metastatic Colorectal Cancer, run by Korea University Anam Hospital at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 23 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 8 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximum Tolerated Dose (time frame: Up to approximately 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05990543.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in